About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:4942362
Allelic
Composition
Tg(Kit*D814V)3Roer/0
Tg(Mx1-cre)1Cgn/0
Genetic
Background
involves: C57BL/6 * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Kit*D814V)3Roer mutation (0 available)
Tg(Mx1-cre)1Cgn mutation (6 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• 1 pIpC treated mouse was euthanized due to severe disease at 12 weeks of age (J:169611)
• 1 pIpC treated mouse was euthanized due to severe disease at 12 weeks of age (J:169611)

digestive/alimentary system
• in mice with intestinal inflammation (J:169611)
• in mice with intestinal inflammation (J:169611)
• in mice with intestinal inflammation (J:169611)
• in mice with intestinal inflammation (J:169611)
• diarrhea with bloody feces is seen in mice with intestinal inflammation (J:169611)
• diarrhea with bloody feces is seen in mice with intestinal inflammation (J:169611)
• in a few mice, regardless of pIpC treatment (J:169611)
• in a few mice, regardless of pIpC treatment (J:169611)
• rare (J:169611)
• rare (J:169611)

hematopoietic system
• most of the mast cells in pIpC treated mice with mastocytosis are round with some degree of hypergranulation and only few spindle shaped cells are seen (J:169611)
• most of the mast cells in pIpC treated mice with mastocytosis are round with some degree of hypergranulation and only few spindle shaped cells are seen (J:169611)
• mice treated with 3 injections of pIpC every second day at 4 to 10 weeks of age develop diffuse mastocytosis by 13 - 38 weeks of age (J:169611)
• pIpC treated mice display a variable increase in cutaneous mast cell numbers (J:169611)
• in some pIpC treated mice accumulations of mast cells are seen in the lymph nodes (J:169611)
• mice not treated with pIpC develop phenotypes similar to those in pIpC injected mice (J:169611)
• mice treated with 3 injections of pIpC every second day at 4 to 10 weeks of age develop diffuse mastocytosis by 13 - 38 weeks of age (J:169611)
• pIpC treated mice display a variable increase in cutaneous mast cell numbers (J:169611)
• in some pIpC treated mice accumulations of mast cells are seen in the lymph nodes (J:169611)
• mice not treated with pIpC develop phenotypes similar to those in pIpC injected mice (J:169611)
• in mice with leukemia (J:169611)
• in mice with leukemia (J:169611)
• bone marrow cells are unable to engraft in nonirradiated recipient mice (J:169611)
• bone marrow cells are unable to engraft in nonirradiated recipient mice (J:169611)

tumorigenesis
• some pIpC treated mice develop large numbers of dermal mast cell tumors of variable size (J:169611)
• in a few mice these tumors are macroscopically visible (J:169611)
• mice not treated with pIpC develop phenotypes similar to those in pIpC injected mice (J:169611)
• some pIpC treated mice develop large numbers of dermal mast cell tumors of variable size (J:169611)
• in a few mice these tumors are macroscopically visible (J:169611)
• mice not treated with pIpC develop phenotypes similar to those in pIpC injected mice (J:169611)
• some mice, regardless of pIpC treatment, develop a condition resembling B-lymphoblastic leukemia (J:169611)
• some mice, regardless of pIpC treatment, develop a condition resembling B-lymphoblastic leukemia (J:169611)

growth/size/body
• in mice with intestinal inflammation (J:169611)
• in mice with intestinal inflammation (J:169611)

integument
• some pIpC treated mice develop large numbers of dermal mast cell tumors of variable size (J:169611)
• in a few mice these tumors are macroscopically visible (J:169611)
• mice not treated with pIpC develop phenotypes similar to those in pIpC injected mice (J:169611)
• some pIpC treated mice develop large numbers of dermal mast cell tumors of variable size (J:169611)
• in a few mice these tumors are macroscopically visible (J:169611)
• mice not treated with pIpC develop phenotypes similar to those in pIpC injected mice (J:169611)

immune system
• in a few mice, regardless of pIpC treatment (J:169611)
• in a few mice, regardless of pIpC treatment (J:169611)
• rare (J:169611)
• rare (J:169611)
• most of the mast cells in pIpC treated mice with mastocytosis are round with some degree of hypergranulation and only few spindle shaped cells are seen (J:169611)
• most of the mast cells in pIpC treated mice with mastocytosis are round with some degree of hypergranulation and only few spindle shaped cells are seen (J:169611)
• mice treated with 3 injections of pIpC every second day at 4 to 10 weeks of age develop diffuse mastocytosis by 13 - 38 weeks of age (J:169611)
• pIpC treated mice display a variable increase in cutaneous mast cell numbers (J:169611)
• in some pIpC treated mice accumulations of mast cells are seen in the lymph nodes (J:169611)
• mice not treated with pIpC develop phenotypes similar to those in pIpC injected mice (J:169611)
• mice treated with 3 injections of pIpC every second day at 4 to 10 weeks of age develop diffuse mastocytosis by 13 - 38 weeks of age (J:169611)
• pIpC treated mice display a variable increase in cutaneous mast cell numbers (J:169611)
• in some pIpC treated mice accumulations of mast cells are seen in the lymph nodes (J:169611)
• mice not treated with pIpC develop phenotypes similar to those in pIpC injected mice (J:169611)
• in mice with leukemia (J:169611)
• in mice with leukemia (J:169611)

Mouse Models of Human Disease
OMIM ID Ref(s)
Mast Cell Disease 154800 J:169611


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Tumor Biology (MTB), Gene Ontology (GO), MouseCyc
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
02/02/2016
MGI 6.02
The Jackson Laboratory